Article Figures & Data
Tables
Administered activity Spleen (organ receiving largest dose) Effective dose Radiopharmaceutical MBq mCi mGy/MBq rad/mCi mSv/MBq rem/mCi 111In-pentetreotide 222 6 0.57 2.1 0.054 0.20 ↵* Adapted from ICRP 106 (37).
Weight-adjusted administered activity Spleen (organ receiving largest dose) Effective dose Radiopharmaceutical MBq/kg mCi/kg mGy/MBq rad/mCi mSv/MBq rem/mCi 111In-pentetreotide 3 0.08 0.79 2.9 0.071 0.26 * Adapted from ICRP 106 (37).
Weight-adjusted administered activity Spleen (organ receiving largest dose) Effective dose Radiopharmaceutical MBq/kg mCi/kg mGy/MBq rad/mCi mSv/MBq rem/mCi 111In-pentetreotide 3 0.08 1.8 6.7 0.16 0.59 * Adapted from ICRP 106 (37).
Stage of gestation mGy/MBq rad/mCi mGy rad Early 0.082 0.30 18 1.8 3 mo 0.060 0.22 13 0.13 6 mo 0.035 0.13 7.8 0.78 9 mo 0.031 0.11 6.9 0.69
Jump to section
- Article
- Abstract
- PREAMBLE
- I. INTRODUCTION
- II. GOALS
- III. DEFINITIONS
- IV. EXAMPLES OF CLINICAL AND RESEARCH INDICATIONS
- V. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL (IN THE UNITED STATES)
- VI. PROCEDURE/SPECIFICATIONS OF THE EXAMINATION
- VII. DOCUMENTATION/REPORTING
- VIII. EQUIPMENT SPECIFICATION
- IX. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION CONCERNS
- X. RADIATION SAFETY IN IMAGING
- XI. ISSUES REQUIRING FURTHER CLARIFICATION
- Acknowledgments
- XIV. APPROVAL
- Footnotes
- XIII. REFERENCES
- Figures & Data
- Info & Metrics
Related Articles
Cited By...
- Can 68Ga-DOTA Peptides Be Potential Radiotracers for PET Imaging of the Spleen?
- Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine
- Improving Tools and Options for the Management of Patients with Neuroendocrine Tumors: A Patient Perspective
- 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
- Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms
- 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients
- Carcinoid syndrome caused by a serotonin-secreting pituitary tumour
- Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study
- Updated Practice Guideline for Somatostatin Receptor Scintigraphy